Threshold framing inflates embryo‑selection benefits

Companies that sell polygenic embryo selection often report percent risk reductions based on liability‑threshold models and binary disease cutoffs. Small downward shifts in a continuous trait (e.g., BMI) can look like large reductions in 'disease' incidence when an arbitrary threshold is used, misrepresenting the true phenotypic or clinical benefit. — If policymakers, clinicians, and prospective parents take those framed risk numbers at face value, markets and regulation will develop around an inflated sense of benefit, driving ethical, economic and health‑policy consequences.